Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs.
Clin Cancer Res. 2021 Jan 1;27(1):189-201. doi: 10.1158/1078-0432.CCR-19-1871. Epub 2020 Oct 7.
Clin Cancer Res. 2021.
PMID: 33028591